First successful nGBM and rGBM trial in nearly 3 decades. Unseen long tail survival data. This does not come cheap or quick. While some want to highlight the inefficiencies of our drug development system, that is in the past. Write your congressman/woman if you want to become a champion to fix the system.
The trial is over and the data is great. Lets move on to relevant topics.
As far as the comment:
Man what a trainwreck from a trial design and management standpoint.
Appreciate your opinion but experts, the MHRA and the FDA disagree with your assertion.
I just have several questions and I would appreciate your honest answers.
1. Can you explain why over 90% percent patients were recruited in the last five years of the trial?
2. If everything is as bad as you depict, why did BMY come for collaboration with NWBO? BMY seems like holding no grievance after the collaboration deal was withdrawn last and plans to collaborate on another combo trial.
3. You do know the expanded access program for dcvax which started about the time when the trial was finished. How could FDA approve such program if DcVax had a bad record and after the partial hold?
4. The data from Linda Liau's latest present which has close 60% patients living over 800 days is based on dcvax. You would agree, right?
5. Do you agree that there were patients who dropped out the trial because the pseudoprogression was unknown back then and was considered as true progression?